Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6239180 | AVERITAS | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
Jun, 2021
(2 years ago) | |
US10869827 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(7 months ago) | |
US10463598 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(7 months ago) | |
US8889113 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(7 months ago) | |
US8263059 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(7 months ago) | |
US10034841 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer |
Sep, 2025
(1 year, 4 months from now) | |
US9226903 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer |
Dec, 2028
(4 years from now) | |
US8821920 | AVERITAS | Therapeutic patch for transdermal delivery of capsaicin |
Mar, 2030
(5 years from now) |
Qutenza is owned by Averitas.
Qutenza contains Capsaicin.
Qutenza has a total of 8 drug patents out of which 5 drug patents have expired.
Expired drug patents of Qutenza are:
Qutenza was authorised for market use on 16 November, 2009.
Qutenza is available in patch;topical dosage forms.
Qutenza can be used as method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area.
Drug patent challenges can be filed against Qutenza from 16 November, 2013.
The generics of Qutenza are possible to be released after 26 March, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-838) | Jul 17, 2023 |
Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area
Dosage: PATCH;TOPICAL